Inhibikase Therapeutics, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (12)

Latest Posts

About This Stock More About This Stock
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
Article By: Bio Deep Dives
Wednesday, May 24, 2023 9:55 AM EDT
IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.
In this article: IKT
Read
Inhibikase Targets A Substantial Market Following Results Presented At The Barcelona Conference
Article By: Moon Kil Woong
Monday, March 28, 2022 9:26 AM EDT
The upcoming trial results are expected to show an excellent safety profile of the drug and perhaps some biomarkers that translate into efficacy.
In this article: IKT
Read
Inhibikase Therapeutics: Targeted Therapies That Can Improve Quality Of Life
Article By: Ari Zoldan
Thursday, June 17, 2021 12:10 PM EDT
If the company gets the approval for IkT-148009, which is the company’s lead small drug candidate, and any progress is seen in other drug candidates, the shareholder value creation will be significantly greater than the projection mentioned above.
In this article: IKT Also: ABV, AZN, BIIB, DNLI
Read

Latest Tweets for $IKT

No tweets yet!

PARTNER HEADLINES

$IKT

Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
Dick Kaplan 5/25/2023 12:54:35 PM

Bio Deep Dives, very thorough piece on #Inhibikase.  But could you go into more depth about the competative landscape?  Intersted in $IKT but wondering how the competition measures up.

Inhibikase Targets A Substantial Market Following Results Presented At The Barcelona Conference
Kurt Benson 3/31/2022 8:40:01 PM

Good analysis. Sounds like there's tremendous potential for $IKT!

1 to 3 of 3 comments